Polyclonal Antibody Therapies for Clostridium difficile Infection
AbstractClostridium difficile infection has emerged as a growing worldwide health problem. The colitis of Clostridium difficile infection results from the synergistic action of C. difficile secreted toxins A and B upon the colon mucosa. A human monoclonal IgG anti-toxin has demonstrated the ability in combination therapy to reduce mortality in C. difficile challenged hamsters. This antibody is currently in a clinical trial for the treatment of human Clostridium difficile infection. More than one group of investigators has considered using polyclonal bovine colostral antibodies to toxins A and B as an oral passive immunization. A significant proportion of the healthy human population possesses polyclonal antibodies to the Clostridium difficile toxins. We have demonstrated that polyclonal IgA derived from the pooled plasma of healthy donors possesses specificity to toxins A and B and can neutralize these toxins in a cell-based assay. This suggests that secretory IgA prepared from such pooled plasma IgA may be able to be used as an oral treatment for Clostridium difficile infection. View Full-Text
Share & Cite This Article
Simon, M.R.; Chervin, S.M.; Brown, S.C. Polyclonal Antibody Therapies for Clostridium difficile Infection. Antibodies 2014, 3, 272-288.
Simon MR, Chervin SM, Brown SC. Polyclonal Antibody Therapies for Clostridium difficile Infection. Antibodies. 2014; 3(4):272-288.Chicago/Turabian Style
Simon, Michael R.; Chervin, Stephanie M.; Brown, Stephen C. 2014. "Polyclonal Antibody Therapies for Clostridium difficile Infection." Antibodies 3, no. 4: 272-288.